Template:Amlodipine: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 12: | Line 12: | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amlodipine contraindications|Contraindications]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amlodipine contraindications|Contraindications]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amlodipine warnings|Warnings | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amlodipine warnings and precautions|Warnings and Precautions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amlodipine adverse reactions|Adverse Reactions]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Amlodipine adverse reactions|Adverse Reactions]] |
Latest revision as of 06:41, 13 March 2014
Amlodipine |
---|
NORVASC®, AMLODIPINE®, AMLODIPINE BESYLATE® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Dosage Forms and Strengths |
Contraindications |
Warnings and Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
Clinical Studies |
How Supplied/Storage and Handling |
Patient Counseling Information |
Labels and Packages |
Clinical Trials on Amlodipine |
ClinicalTrials.gov |